var data={"title":"Aminocaproic acid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminocaproic acid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5612?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminocaproic-acid-drug-information\" class=\"drug drug_general\">see &quot;Aminocaproic acid: Drug information&quot;</a> and <a href=\"topic.htm?path=aminocaproic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminocaproic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133225\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amicar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056453\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Hemostatic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673263\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients:</b> Limited data available: IV: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180-200 seconds has been used (Downard, 2003; Horwitz, 1998; Wilson, 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of perioperative bleeding associated with cardiac surgery:</b> Limited data available: IV: 75 mg/kg administered at the beginning and end of cardiopulmonary bypass, along with 75 mg/100 mL added to the priming fluid for cardiopulmonary bypass (Martin, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056447\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=aminocaproic-acid-drug-information\" class=\"drug drug_general\">see &quot;Aminocaproic acid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Control of hemorrhage (oral, epistaxis, menorrhagia) in hemophilic patients, adjunct treatment:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b> (Acharya, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Control of mucosal bleeding in thrombocytopenia/platelet dysfunction:</b> Limited data available: Infants, Children, and Adolescents: Oral, IV: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b> (Bussel, 2011; Lipton, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Hematuria (gross; upper tract), refractory:</b> Limited data available: Children &ge;11 years and Adolescents: Oral: 100 mg/kg/dose every 6 hours; continue for 2 days beyond resolution of hematuria; dosing based on case series (n=4) which showed hematuria resolution within 2-7 days; risks and benefits must be weighed prior to use (Kaye, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prevention of bleeding associated with dental procedures in hemophilic patients:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50-100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b>; used in conjunction with DDAVP or factor replacement therapy; continue for up to 7 days or until mucosal healing is complete (Acharya, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients:</b> Limited data available: Infants, Children, and Adolescents: IV: 100 mg/kg prior to or immediately after cannulation, followed by 25-30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180-200 seconds has been used (Downard, 2003; Horwitz, 1998; Wilson, 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prevention of perioperative bleeding associated with cardiac surgery:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children &lt;2 years: Dosing regimens variable: IV: In the largest trial (n=120, all patients &lt;20 kg), a dose of 75 mg/kg was administered at the beginning and end of cardiopulmonary bypass (CPB), and 75 mg/100 mL was added to the CPB priming fluid (Martin, 2011a). Another study group in two separate trials (n=110, age range: 2 months to 14 years) used a 100 mg/kg dose after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of three doses (Chauhan, 2000; Chauhan, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;2 years and Adolescents: IV: 100 mg/kg after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses; regimen used in two separate trials (n=110, age range: 2 months to 14 years) (Chauhan, 2000; Chauhan, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis):</b> Limited data available: Children &ge;11 years and Adolescents: IV: 100 mg/kg (maximum dose: 5 <b>g</b>) administered over 15-20 minutes after induction, followed by a continuous IV infusion of 10 mg/kg/hour for the remainder of the surgery; discontinued at time of wound closure (Florentino-Pineda, 2001; Florentino-Pineda, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Traumatic hyphema:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50-100 mg/kg/dose every 4 hours for 5 days; maximum daily dose: 30 <b>g/day</b> (Brandt, 2001; Crouch, 1999; Teboul, 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Acute bleeding:</b> Oral, IV: Loading dose: 4-5 <b>g</b> during the first hour, followed by 1 <b>g</b>/hour for 8 hours (or 1.25 <b>g</b>/hour using oral solution) or until bleeding controlled (maximum daily dose: 30 <b>g</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> There are no dosage adjustments are provided in the manufacturer's labeling, but aminocaproic acid may accumulate in patients with decreased renal function; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no dosage adjustments are provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133202\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 25% (236.5 mL) [contains edetate disodium, methylparaben, propylparaben, saccharin sodium; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 25% (473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25% (237 mL [DSC], 473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 1000 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg [DSC], 1000 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056458\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May administer without regard to food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Do not administer undiluted; rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV infusion: After further dilution, administer over 15 to 60 minutes (rate dependent upon use).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: Must further dilute prior to administration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133219\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials, tablets, and syrup at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze injection or syrup. Solutions diluted for IV use in D<sub>5</sub>W or NS to concentrations of 10-100 mg/mL are stable at 4&deg;C (39&deg;F) and 23&deg;C (73&deg;F) for 7 days (Zhang, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056457\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis) (FDA approved in adults); has also been used for traumatic hyphema, prevention of perioperative bleeding, refractory hematuria, and prevention of bleeding associated with ECMO in high-risk patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133270\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amicar may be confused with amikacin, Amikin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amicar [US] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133267\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash, pruritus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dry ejaculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site necrosis, injection site pain, injection site reactions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Vision decreased, watery eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, nasal congestion, pulmonary embolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hepatic lesion, hyperkalemia, myocardial lesion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133208\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intrarenal obstruction: May occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skeletal muscle weakness: Ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use. Monitor CPK; discontinue treatment with a rise in CPK.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may accumulate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood products: Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Do not administer without a definite diagnosis of laboratory findings indicative of hyperfibrinolysis. Inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of DIC. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IV administration: Avoid rapid IV administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298735\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133195\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12564&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-inhibitor Coagulant Complex (Human): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor IX Complex (Human) [(Factors II, IX, X)]: Aminocaproic Acid may enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, use of this combination may increase the risk of thrombosis. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133198\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133211\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056452\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fibrinogen, fibrin split products, serum creatinine kinase (long-term therapy); serum potassium, BUN, creatinine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056456\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic concentration: &gt;130 mcg/mL (concentration necessary for inhibition of fibrinolysis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds competitively to plasminogen; blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin, resulting in inhibition of fibrin degradation (fibrinolysis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133207\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~1 to 72 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely through intravascular and extravascular compartments; V<sub>d</sub>: Oral: 23 L;  IV: 30 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1.2 &plusmn; 0.45 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (65% as unchanged drug, 11% as metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133210\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amicar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 g/mL (236.5 mL): $2,890.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aminocaproic Acid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/mL (20 mL): $7.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amicar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $732.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (30): $1,465.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038523\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acepramin (HN, HU);</li>\n      <li>Acidum e-aminocapronicum (PL);</li>\n      <li>AKK (UA);</li>\n      <li>Amicar (AE, AU, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Caproamin (VE);</li>\n      <li>Caprolest (NL);</li>\n      <li>Caprolex (BD);</li>\n      <li>Caprolisin (IT);</li>\n      <li>Darnitsa (UA);</li>\n      <li>EAC (DE);</li>\n      <li>Epsamon (CH);</li>\n      <li>Epsicaprom (PT);</li>\n      <li>Epsikapron (QA, SA);</li>\n      <li>Epsilon (FI);</li>\n      <li>Hamostat (IN);</li>\n      <li>Hemolysin (BD);</li>\n      <li>Hexalense (FR);</li>\n      <li>Inselon (TW);</li>\n      <li>Ipron (TW);</li>\n      <li>Ipsilon (AR, BR, JP, PY, UY);</li>\n      <li>Kai Nai Yin (CN);</li>\n      <li>Kaposelin (UA);</li>\n      <li>Minocap (BD);</li>\n      <li>Plaslloid (TW);</li>\n      <li>Resplamin (JP);</li>\n      <li>Syrop acidi e-aminocapronici (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acharya S, &quot;Hemostatic Disorders,&quot; <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 402-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brandt MT and Haug RH, &quot;Traumatic Hyphema: A Comprehensive Review,&quot; <i>J Oral Maxillofac Surg</i>, 2001, 59(12):1462-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/11732035/pubmed\" target=\"_blank\" id=\"11732035\">11732035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bussel J and Renaud T, &quot;Disorders of Platelets,&quot; <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 372.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chauhan S, Das SN, Bisoi A, et al, &quot;Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 2004, 18(2):141-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/15073700/pubmed\" target=\"_blank\" id=\"15073700\">15073700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chauhan S, Kumar BA, Rao BH, et al, &quot;Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease,&quot; <i>Ann Thorac Surg</i>, 2000, 70(4):1308-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/11081890/pubmed\" target=\"_blank\" id=\"11081890\">11081890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crouch ER Jr and Crouch ER, &quot;Management of Traumatic Hyphema: Therapeutic Options,&quot; <i>J Pediatr Ophthalmol Strabismus</i>, 1999, 36(5):238-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/10505828/pubmed\" target=\"_blank\" id=\"10505828\">10505828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Downard CD, Betit P, Chang RW, et al, &quot;Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review,&quot; <i>J Pediatr Surg</i>, 2003, 38(8):1212-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/12891495/pubmed\" target=\"_blank\" id=\"12891495\">12891495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Florentino-Pineda I, Blakemore LC, Thompson GH, et al, &quot;The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study,&quot; <i>Spine (Phila Pa 1976)</i>, 2001, 26(10):1147-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/11413428/pubmed\" target=\"_blank\" id=\"11413428\">11413428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, &quot;The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study,&quot; <i>Spine (Phila Pa 1976)</i>, 2004, 29(3):233-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/14752343/pubmed\" target=\"_blank\" id=\"14752343\">14752343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horwitz JR, Cofer BR, Warner BW, et al, &quot;A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO,&quot; <i>J Pediatr Surg</i>, 1998, 33(11):1610-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/9856877/pubmed\" target=\"_blank\" id=\"9856877\">9856877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaye JD, Smith EA, Kirsch AJ, et al, &quot;Preliminary Experience With Epsilon Aminocaproic Acid for Treatment of Intractable Upper Tract Hematuria in Children With Hematological Disorders,&quot; <i>J Urol</i>, 2010, 184(3):1152-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/20650477/pubmed\" target=\"_blank\" id=\"20650477\">20650477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipton JM, &quot;Bone Marrow Failure,&quot; <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 131.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin K, Breuer T, Gertler R, et al, &quot;Tranexamic Acid Versus &epsilon;-Aminocaproic Acid: Efficacy and Safety in Paediatric Cardiac Surgery,&quot; <i>Eur J Cardiothorac Surg</i>, 2011a, 39(6):892-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/21115357/pubmed\" target=\"_blank\" id=\"21115357\">21115357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin K, Gertler R, Liermann H, et al, &quot;Switch From Aprotinin to &epsilon;-Aminocaproic Acid: Impact on Blood Loss, Transfusion, and Clinical Outcome in Neonates Undergoing Cardiac Surgery,&quot; <i>Br J Anaesth</i>, 2011, 107(6):934-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/21857014/pubmed\" target=\"_blank\" id=\"21857014\">21857014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teboul BK, Jacob JL, Barsoum-Homsy M, et al, &quot;Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,&quot; <i>Ophthalmology</i>, 1995, 102(11):1646-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/9098257/pubmed\" target=\"_blank\" id=\"9098257\">9098257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams GD, Bratton SL, Riley EC, et al, &quot;Efficacy of Epsilon-Aminocaproic Acid in Children Undergoing Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 1999, 13(3):304-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/10392682/pubmed\" target=\"_blank\" id=\"10392682\">10392682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson JM, Bower LK, Fackler JC, et al, &quot;Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO,&quot; <i>J Pediatr Surg</i>, 1993, 28(4):536-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminocaproic-acid-pediatric-drug-information/abstract-text/8483066/pubmed\" target=\"_blank\" id=\"8483066\">8483066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang YP, Trissel LA. Stability of aminocaproic acid injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection. <i>Int J Pharm Compound</i>. 997;1(2):132-134.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12564 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F133225\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056453\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F15673263\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056447\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133202\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F133186\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056458\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F133219\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056457\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133270\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133267\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133208\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298735\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133195\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F133198\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133211\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056452\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1056456\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F133207\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133210\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038523\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12564|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminocaproic-acid-drug-information\" class=\"drug drug_general\">Aminocaproic acid: Drug information</a></li><li><a href=\"topic.htm?path=aminocaproic-acid-patient-drug-information\" class=\"drug drug_patient\">Aminocaproic acid: Patient drug information</a></li></ul></div></div>","javascript":null}